Cabazitaxel Method Claims Unpatentable

September 21, 2017

MYLAN LABORATORIES LIMITED, (Petitioner)
v.
AVENTIS PHARMA S.A. (Patent Owner)

Case IPR2016-00712
Patent 8,927,592 B2

The PTAB ordered that Sanofi’s (Aventis Pharma S.A.) patent claims to uses of Cabazitaxel have been proved to be unpatentable by a preponderance of the evidence.

Cabazitaxel

Cabazitaxel

4α-acetoxy-2α-benzoyloxy-5β, 20-epoxy-lβ-hydroxy-7β, 10β-dimethoxy-9-oxo-ll-taxen-13α-yl(2R,3S)-3tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.